Drug Safety Through Maternal Fetal Pharmacovigilance Data Integration

Abstract

Maternal-fetal pharmacovigilance is an evolving discipline focused on monitoring, assessing, and preventing adverse drug reactions during pregnancy, with the ultimate goal of ensuring drug safety for both the mother and fetus. Integrating data from diverse pharmacovigilance sources into a cohesive framework is critical for robust risk assessment and optimal clinical decision-making. This article reviews the burden of drug-related adverse events in pregnancy, current data integration approaches, underlying mechanisms of drug transfer and toxicity, risk factors, clinical features, diagnostic strategies, therapeutic management, recent advances, and guideline recommendations. Practical and clinically relevant considerations are discussed with emphasis on the need for comprehensive, real-time maternal-fetal pharmacovigilance systems to improve outcomes and inform evidence-based care.

Introduction

Pregnant women represent a unique population in pharmacotherapy, as drug exposure can impact both maternal health and fetal development. Despite the exclusion of pregnant women from most pre-marketing clinical trials, medication use in pregnancy is common, driven by chronic illnesses, acute conditions, and pregnancy-specific complications. The lack of robust safety data often leads to uncertainty in risk-benefit assessments, underscoring the importance of effective pharmacovigilance. Integration of maternal and fetal pharmacovigilance data enables improved detection of adverse drug events (ADEs), facilitates mechanistic understanding, and supports timely regulatory and clinical responses. This review examines the scientific and clinical imperatives of data integration in maternal-fetal pharmacovigilance, drawing on recent evidence and practice guidelines.

Epidemiology / Disease Burden

Globally, more than 80% of pregnant women are exposed to at least one prescription or over-the-counter medication during pregnancy. Adverse drug reactions (ADRs) in this population can result in maternal morbidity, fetal growth restriction, congenital anomalies, preterm birth, or perinatal death. Epidemiological studies estimate that up to 2-3% of congenital malformations are attributable to drug exposures. However, the true burden of drug-related harm remains underestimated due to underreporting, variations in pharmacovigilance infrastructure, and challenges in attributing causality. The need for harmonized data collection and cross-jurisdictional data sharing is increasingly recognized as a priority for maternal-fetal health.

Pathophysiology

Drug safety in pregnancy is influenced by maternal physiological adaptations, placental drug transfer, and fetal pharmacodynamics. Pregnancy alters drug absorption, distribution, metabolism, and excretion, often necessitating dosage adjustments. The placenta serves as both a barrier and conduit for drug passage, with transfer governed by molecular weight, lipid solubility, protein binding, and the presence of transporters. Fetal susceptibility to drug toxicity varies by gestational age, organogenesis, and genetic factors. Mechanisms of teratogenicity include disruption of cell proliferation, differentiation, and apoptosis, as well as interference with signaling pathways critical for fetal development. Understanding these mechanisms is essential for interpreting pharmacovigilance data and guiding clinical practice.

Risk Factors

Risk factors for drug-induced harm in pregnancy include maternal comorbidities (e.g., epilepsy, hypertension, diabetes), polypharmacy, genetic polymorphisms affecting drug metabolism, and concomitant exposure to substances such as alcohol, tobacco, or illicit drugs. Timing of exposure relative to key developmental windows, particularly during the first trimester, significantly modulates risk. Socioeconomic barriers to prenatal care and medication adherence further compound vulnerability. Identification and stratification of these risk factors through integrated pharmacovigilance databases enable personalized risk assessment and targeted interventions.

Clinical Features

Clinical manifestations of maternal-fetal drug toxicity are heterogeneous, ranging from mild transient effects (e.g., neonatal withdrawal, sedation) to severe outcomes such as structural malformations, neurodevelopmental impairment, or intrauterine fetal demise. Maternal features may include altered mental status, organ dysfunction, or exacerbation of pre-existing conditions. Recognition of characteristic clinical patterns, supported by temporal associations and exclusion of alternative etiologies, is critical for prompt diagnosis and intervention.

Diagnosis

Diagnosis of drug-related adverse events in pregnancy requires a high index of suspicion and comprehensive history-taking, including detailed medication exposure timelines. Diagnostic workup may involve targeted laboratory assays, fetal imaging (ultrasound, MRI), and functional assessments such as fetal heart rate monitoring. Causality assessment tools, such as the Naranjo algorithm and the WHO-UMC system, aid in standardizing case evaluation. Integration of individual case safety reports (ICSRs) with population-level data enhances signal detection and diagnostic accuracy.

Treatment & Management

Management strategies for drug-induced adverse events in pregnancy prioritize maternal stabilization, cessation or substitution of the offending agent, and fetal surveillance. Multidisciplinary collaboration among obstetricians, clinical pharmacologists, neonatologists, and pharmacists is essential. Supportive care, specific antidotes, or emergency interventions (e.g., preterm delivery) may be warranted depending on severity. Preconception counseling and shared decision-making are recommended for women with chronic conditions requiring pharmacotherapy, to balance maternal and fetal risks and benefits.

Recent Advances / Emerging Therapies

Recent advances in maternal-fetal pharmacovigilance include the development of real-world evidence platforms, use of electronic health records (EHRs) for active surveillance, and application of artificial intelligence (AI) for signal detection. International collaborations, such as the IMI ConcePTION and EUROmediSAFE projects, are driving the creation of large-scale, interoperable databases that link maternal and pediatric outcomes. Novel biomarkers for in utero drug exposure and pharmacogenomic profiling hold promise for precision medicine approaches. Expansion of patient-reported outcomes and mobile health (mHealth) tools further enhances data granularity and timeliness, supporting rapid regulatory and clinical responses to emerging safety concerns.

Guideline Recommendations

Leading regulatory agencies, including the FDA and EMA, advocate for systematic post-marketing pharmacovigilance in pregnancy, proactive risk communication, and integration of maternal-fetal safety data into product labeling. Clinical guidelines emphasize individualized risk-benefit assessment, ongoing safety monitoring, and reporting of suspected ADRs. The American College of Obstetricians and Gynecologists (ACOG) and the Royal College of Obstetricians and Gynaecologists (RCOG) recommend multidisciplinary review of complex cases, use of evidence-based prescribing resources, and involvement of patients in shared decision-making. Standardization of data elements, harmonization of reporting systems, and international data sharing are prioritized to improve the evidence base and inform safer pharmacotherapy in pregnancy.

Conclusion

Drug safety in pregnancy remains a complex and evolving challenge, with significant implications for maternal and fetal health. Integration of maternal-fetal pharmacovigilance data from diverse sources is essential for comprehensive risk assessment, timely signal detection, and informed clinical decision-making. Advances in data integration, real-world evidence, and precision medicine promise to enhance safety surveillance and therapeutic outcomes. Ongoing investment in multidisciplinary research, infrastructure, and international collaboration will be critical to advancing maternal-fetal drug safety and optimizing care for this vulnerable population.